As demonstrated by the Flaura clinical trial (NCT02296125) (PMID 29151359), osimertinib showed an efficacy superior to standard EGFR-TKIs in the first-line of treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.